Telix Pharmaceuticals stock falls after USD 1.65 billion deal

Published on 09/24/2026 at 13:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Telix Pharmaceuticals stock reported H1 2026 revenue of USD 477.3 million, up 22 percent year over year. RBC raised its target to AUD 21 from AUD 19 on September 22, 2026.

Telix, AU000000TLX2, Illustration mit AI erstellt.

Telix Pharmaceuticals stock fell 4.23 percent to AUD 16.08 on the ASX on September 23, 2026, after the radiopharmaceutical company announced a USD 1.65 billion agreement to acquire ITM Isotope Technologies Munich SE. The proposed transaction adds scale to Telix's cancer portfolio but also places new equity issuance at the center of the valuation debate.

ITM deal adds scale and dilution

According to StockTitan, Telix will acquire 100 percent of ITM for USD 1.65 billion upfront, with up to USD 700 million in contingent milestones. The agreement also includes approximately USD 1.25 billion of Telix shares for ITM sellers, making ownership structure as important as the industrial rationale.

The transaction is designed to combine Telix's commercial radiopharmaceutical business with ITM's isotope production and therapeutic development capabilities. Telix shareholders are expected to own 76.3 percent of the combined company after completion, while ITM shareholders would hold 23.7 percent.

Revenue growth supports the strategy

Telix entered the transaction with measurable operating momentum. In H1 2026, revenue reached USD 477.3 million, an increase of 22 percent from the prior-year period, while net profit was USD 38.3 million, according to Quartr. The same H1 2026 update placed second-quarter revenue at USD 247 million and pointed to full-year revenue above USD 1 billion.

That comparison matters because the ITM purchase is not being funded against a stagnant base. Telix's existing growth profile gives management a larger commercial platform, while the share component raises the number of variables investors must assess before completion.

Analyst target moves to AUD 21

Investing.com reported on September 22, 2026, that RBC upgraded Telix to Outperform and lifted its price target from AUD 19 to AUD 21. The analyst view places the target AUD 4.92 above the September 23 ASX price, a 30.6 percent difference, while also reflecting confidence in the combined group's projected revenue above USD 1.3 billion for 2026.

Telix stock trades at AUD 16.08

Telix Pharmaceuticals stock was trading at AUD 16.08 on the ASX on September 23, 2026, down 4.23 percent on the session. Its market capitalization stood at AUD 5.7 billion on the same date, so the USD 1.65 billion upfront consideration represents a material transaction relative to the existing equity value.